IRF family regulates type-I IFN system for anti-tumor immunity through promoting differentiation of B cells, inducing differentiation of naive T cells to effector CD4+ or CD8+T cells and driving the expression of MHC class I and II [40]. Here, TRIM63 is linked to neoplasm.